Drugs / Spirapril
last change Dec 2025 re-read 2 minutes ago

Spirapril

Small molecule targets ACE via inhibition

Developed for
heart disorder · type 2 diabetes mellitus · hypertensive disorder
Investigated by
Martin Huelsmann

Trials 1 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02817360 Feb 2016 → Dec 2025 overdue heart disorder, type 2 diabetes mellitus Martin Huelsmann Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00295542 Comparator Mar 2000 → Apr 2009 hypertensive disorder University of Vigo Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as spirapril Spirapril 24mg/d” NCT02817360
1

NCT00295542

Known as Espirapril ChEMBL registry synonym — accepted as the source's own label CHEMBL431
Known as Renormax ChEMBL registry synonym — accepted as the source's own label CHEMBL431
Known as SCH 33844 ChEMBL registry synonym — accepted as the source's own label CHEMBL431
Known as Spirapril hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL431
Known as SPIRAPRIL HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL431
Action Inhibit “Angiotensin-converting enzyme inhibitor” CHEMBL431
Modality Small molecule CHEMBL431
Target ACE “Angiotensin-converting enzyme inhibitor” CHEMBL431